PDSS1 Inhibitors
Chemical inhibitors of PDSS1 operate through various mechanisms to impede its function in the ubiquinone biosynthesis pathway. Decylubiquinone directly competes with ubiquinone, the natural substrate of PDSS1, effectively reducing the enzyme's ability to catalyze the conversion of 4-hydroxybenzoate to polyprenyl-4-hydroxybenzoate. This competitive inhibition is a classic example of how substrate analogs can be used to diminish the activity of an enzyme. Similarly, Terbinafine and Zaragozic acid A target enzymes upstream of PDSS1. Terbinafine inhibits squalene epoxidase, thereby restricting the availability of farnesyl pyrophosphate (FPP), a precursor required for PDSS1 enzyme activity, while Zaragozic acid A impedes squalene synthase, which also leads to a reduction of FPP levels. Clomazone disrupts the biosynthesis of isoprenoids, crucial precursors for ubiquinone synthesis, which PDSS1 requires for its activity. The reduced availability of these precursors consequentially limits PDSS1 activity.
In addition, a series of inhibitors, including Mevastatin, Lovastatin, Simvastatin, Atorvastatin, and Pravastatin, exert their inhibitory effects by targeting HMG-CoA reductase, an enzyme key to the mevalonate pathway which provides isoprenoid units essential for PDSS1 function. The inhibition of HMG-CoA reductase results in a decreased pool of isoprenoids, thus indirectly restricting PDSS1 activity. Fenofibrate and Rosiglitazone, through activation of PPARα and PPARγ receptors respectively, modulate lipid metabolism in a manner that alters the synthesis and availability of lipids and isoprenoids necessary for the optimal function of PDSS1. Lastly, Pyridaben acts by obstructing the electron transport chain at complex I.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Decylubiquinone | 55486-00-5 | sc-358659 sc-358659A | 10 mg 50 mg | $70.00 $269.00 | 10 | |
Decylubiquinone, an analog of ubiquinone, competes with the natural substrate ubiquinone in the biosynthesis pathway where PDSS1 is critical for converting 4-hydroxybenzoate to polyprenyl-4-hydroxybenzoate. This competition can inhibit the activity of PDSS1 by substrate competition. | ||||||
Terbinafine | 91161-71-6 | sc-338609 | 100 mg | $560.00 | 1 | |
Terbinafine inhibits squalene epoxidase, an enzyme upstream of the PDSS1 step in the cholesterol biosynthesis pathway. Inhibition of squalene epoxidase leads to a depletion of farnesyl pyrophosphate (FPP), which is a substrate necessary for PDSS1 function. | ||||||
Clomazone | 81777-89-1 | sc-234404 | 100 mg | $119.00 | ||
Clomazone is known to inhibit the biosynthesis of isoprenoids, which are precursors for ubiquinone synthesis. PDSS1 requires isoprenoid units for its function, hence inhibition of their synthesis can indirectly inhibit PDSS1. | ||||||
Mevastatin (Compactin) | 73573-88-3 | sc-200853 sc-200853A | 10 mg 50 mg | $77.00 $179.00 | 18 | |
Mevastatin is a competitive inhibitor of HMG-CoA reductase, an early enzyme in the mevalonate pathway. Inhibition of this enzyme decreases the overall pool of isoprenoids, which are necessary for PDSS1 function, thereby indirectly inhibiting PDSS1. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $29.00 $90.00 $339.00 | 12 | |
Lovastatin inhibits HMG-CoA reductase, leading to decreased production of isoprenoids. As these isoprenoid units are essential for PDSS1 activity in ubiquinone synthesis, this results in functional inhibition of PDSS1. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $31.00 $89.00 $135.00 $443.00 | 13 | |
Simvastatin, another HMG-CoA reductase inhibitor, diminishes the supply of isoprenoids needed for PDSS1 activity, thereby indirectly inhibiting the function of PDSS1 in coenzyme Q biosynthesis. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $257.00 $505.00 | 9 | |
Atorvastatin inhibits HMG-CoA reductase, thus reducing the synthesis of isoprenoids, which are substrates for ubiquinone synthesis. This shortage in substrate availability indirectly inhibits the enzymatic function of PDSS1. | ||||||
Pravastatin, Sodium Salt | 81131-70-6 | sc-203218 sc-203218A sc-203218B | 25 mg 100 mg 1 g | $69.00 $162.00 $787.00 | 2 | |
Pravastatin blocks HMG-CoA reductase, leading to less synthesis of isoprenoids. Since PDSS1 requires these isoprenoids for ubiquinone synthesis, its function is indirectly inhibited by pravastatin. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
Fenofibrate activates peroxisome proliferator-activated receptor alpha (PPARα) which influences the expression of genes involved in lipid metabolism, potentially altering the availability of precursors required for PDSS1's enzymatic activity, and thus can indirectly inhibit PDSS1. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
Rosiglitazone, a PPARγ agonist, alters lipid metabolism and can influence the synthesis of isoprenoids and other lipids that are required for PDSS1 function, thus potentially leading to an indirect inhibition of PDSS1 enzymatic activity. | ||||||